Cargando…

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

BACKGROUND: In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD). Yearly medical costs related to T2D and CKD account for approximately €1.3 billion and €805 million, respectively. The FIDELIO-DKD tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quist, Sara W., van Schoonhoven, Alexander V., Bakker, Stephan J. L., Pochopień, Michał, Postma, Maarten J., van Loon, Jeanni M. T., Paulissen, Jeroen H. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685667/ https://www.ncbi.nlm.nih.gov/pubmed/38017448 http://dx.doi.org/10.1186/s12933-023-02053-6

Ejemplares similares

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
por: Quist, S. W., et al.
Publicado: (2023)

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review
por: van Schoonhoven, Alexander V., et al.
Publicado: (2019)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
por: Ashjian, Emily, et al.
Publicado: (2023)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom
por: Zeevat, F, et al.
Publicado: (2021)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
por: Simons, Joost J.M., et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?
por: Urbanus, Anouk T., et al.
Publicado: (2013)

Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Publicado: (2022)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA
por: Zhang, Rong M
Publicado: (2023)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
por: Rozenbaum, Mark H, et al.
Publicado: (2011)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

The personal burden for caregivers of children with phenylketonuria: A cross-sectional study investigating time burden and costs in the UK
por: MacDonald, Anita, et al.
Publicado: (2016)

Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2022)

The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands
por: Al Khayat, Mohamed N.M.T., et al.
Publicado: (2020)

Meningococcal Serogroup A, C, W(135) and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands
por: Hepkema, Hiltsje, et al.
Publicado: (2013)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
por: Shaikh, Aisha, et al.
Publicado: (2022)

Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
por: van Leent, Merlijn W. J., et al.
Publicado: (2015)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhang, Ming-Zhu, et al.
Publicado: (2022)

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis
por: Yasmin, Farah, et al.
Publicado: (2023)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
por: Tu, Hong Anh T, et al.
Publicado: (2013)

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
por: Piccirillo, Francesco, et al.
Publicado: (2023)

An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria
por: Bramlage, Peter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v5clmr7kld226rnt2heesac8ud